|
Published by: Decision Resources
Published: May. 7, 2009 - 26 Pages
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Viruses Cause Debilitating Human Diseases
- Genomics and Antiviral Development
- Current Anti-Infectives Markets
- Major Companies
- Top-Selling Brands
- Impact of Combination Products
- Gilead Sciences’ HIV Franchise
- GlaxoSmithKline’s HIV Franchise
- Antiviral Drug Classes
- Herpes Polymerase Inhibitors
- Nucleoside Analogue Reverse Transcriptase Inhibitors
- Nucleoside Analogues
- Neuraminidase Inhibitors
- Other HIV Antiviral Classes
- Antivirals in Clinical Development
- Small Molecules
- HCV Antivirals
- HIV Antivirals
- New Classes of Antivirals in Clinical Development
- Biologics
- Industry-Shaping Events
- Recent Deals and Business Strategies
- Alnylam and Cubist
- Bristol-Myers Squibb and ZymoGenetics
- GlaxoSmithKline and Pfi zer
- GlaxoSmithKline and Santaris Pharma
- Merck & Co. and Ranbaxy Laboratories
- Pfi zer and Tacere Therapeutics
- Roche and Metabasis Therapeutics
- Market Drivers
- New Mechanisms of Action
- Improved Dosing and Patient Compliance
- Dominance of Small Molecules Over Biologics
- Emerging Markets
- Emerging Viruses
- Outlook
- Tables
- 1. The Link Between Human Viruses and Disease
- 2. Gilead Sciences’ and GlaxoSmithKline’s Major Antiviral HIV Franchises, 2008
- 3. New Classes of Small-Molecule Antivirals in Clinical Development
- 4. Select Monoclonal Antibodies in Clinical Development as Antivirals, 2009
- 5. Select RNA-Based Therapeutics in Development as Antivirals
- Figures
- 1. Growth in the Global Anti-Infectives Markets, 2007-2014
- 2. Major Companies Marketing Antivirals, 2008
- 3. Best-Selling Antiviral Brands, 2008
- 4. Small-Molecule Antivirals by Phase of Clinical Development, 2008
- 5. Market Share of HIV Antiviral Drug Classes, 2007
AbstractIntroduction
The infamous mutability of viruses has long challenged antiviral drug developers, but complete genome sequences are now known for thousands of viruses, and the viral proteins encoded in these sequences are being used as targets for novel antiviral development. Viruses originated early during the evolution of life and have survived by their ability to mutate key genetic sequences in order to evade the defense systems of their hosts.
However, the last 30 years have seen great strides in elucidating the link between viruses and the development and treatment of human diseases. In this report, we evaluate the landscape for antiviral drugs, including antivirals on the market and those in clinical development. We assess novel mechanisms of action, recent deals, industry- shaping events, and market drivers—all of which are important in shaping company business strategies.
Get the Answers You Need to Shape Your Strategy
- Human viruses exist in many different forms and genetic types. What types of viruses exist? What novel mechanisms of action are being exploited in the development of antivirals? What novel fi rst-in-class antivirals are in development?
- Life-cycle management strategies are very important in the antivirals industry. What are the major antiviral franchises? What strategies are these companies using to maintain their market dominance? Why are combination drugs so important?
- The HIV antiretroviral market is dynamic and competitive, comprising more than two dozen agents from six classes. What are the most pressing needs in HIV antivirals? What are the promising emerging therapies? How will the market share of different classes of HIV antivirals change in the near term?
- Because of the side effects of interferon and ribavirin therapies, responses occur in only approximately 40-50% of U.S. patients infected with HCV (genotype 1). What novel HCV therapies are in development?What is Bristol-Myers Squibb’s three-pronged approach to HCV?
- Pfizer’s Research Technology Center’s CSO Arthur M. Krieg, M.D., says RNAi is “potentially a transformational technology for biopharma that makes it worthy of aggressive investment.” What RNA-based antivirals are in development? What RNA-based deals took place recently?
Scope
- Viruses: 2008 Nobel Prize in medicine, viral genome sequences, viral targets, human immunodefi -ciency virus type 1 and type 2, herpesviruses, cytomegalovirus, Epstein Barr virus, herpes simplex virus type 1 and type 2, varicella zoster virus, human papillomavirus, respiratory syncytial virus, hepatitis B virus, hepatitis C virus, infl uenza virus A and B.
- Antiviral markets: Total market size, major franchises, best-selling brands, major companies,blockbuster antivirals, promising HCV antivirals, promising HIV antivirals, fi rst-in-class antivirals in development, emerging markets, swine fl u antivirals.
- Technologies: Biologics, monoclonal antibodies, recombinant proteins, vaccines, small-molecule drugs, RNA-based therapeutics, RNA interference, microRNAs, antisense, pro-drugs, nucleoside analogues, follow-ons, ribozymes, genetically altered stem cells, cell-delivered gene therapy.
- Mechanisms of action: Polymerase inhibitors, nucleoside analogue reverse transcriptase inhibitors (NRTIs), neuraminidase inhibitors, CCR5 antagonists, non-nucleoside reverse transcriptase inhibitors (NNRTIs), fusion inhibitors, integrase inhibitors, protease inhibitors, RNA antagonists, oligonucleotide antagonists.
- Strategies: Life-cycle management, fi xed-dose combinations, pegylation, overcoming drug resistance, drug cocktails, market drivers, novel drug classes.
- Dealmaking: RNA-based deals, a $1.1 billion megadeal, copromotion, upfront payments, milestones, profi t sharing, codevelopment, novel interferons, human proof-of-concept, options.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
